Navigation Links
Study Finds Surfacide UV-C Light Effective as an Adjunct to Infection Control in a Pediatric Burn Hospital
Date:3/27/2017

WAUKESHA, Wis., March 27, 2017 /PRNewswire/ -- A recent study at Shriners Hospitals for Children –  Cincinnati, one of only four freestanding hospitals in the country dedicated to the treatment of pediatric burns and specializing in plastic and reconstructive surgery, concluded that the Surfacide Helios® UV-C Disinfection System is "…an effective and integral component in reducing bacterial pathogens not killed by the EVS (manual) cleaning process alone." The findings were published at the American Burn Association's 49th Annual Meeting in Boston earlier this week. The authors discussed their findings from 234 cultures obtained from rooms and noted a 37 percent organism reduction from terminal cleaning alone. When the Surfacide UV-C Disinfection System was used in addition to the EVS terminal cleaning process, the authors reported a "total elimination of pathogens."

"Surfacide's Helios system incorporates three UV-C energy emitting towers in the patient environment to eradicate drug-resistant organisms, including superbugs such as C. Diff, MRSA, VRE, CRE and Acinetobacter," said Gunner Lyslo, founder and CEO of Surfacide, LLC.  "The system has been shown in studies to significantly reduce the risk of HAIs and lower hospital infection rates." 

Continue Reading
Surfacide Helios(R) UV-C Disinfection System
Surfacide Helios(R) UV-C Disinfection System

The 10-to-20 minute Surfacide disinfection cycle is performed in an unoccupied room, after an environmental services cleaning professional has manually cleaned the area and wiped down surfaces. Treating the room with UV-C energy is an evidence-based disinfection modality disinfecting areas that were not completely cleaned manually.

Other competing systems use just one tower, which is a less effective approach. Single emitter systems, including pulsed xenon gas systems, cannot reach all high-touch surfaces in a single disinfection cycle. Surfacide's multiple emitter approach disinfects an entire room in just one cycle, including the bathroom and other hard-to-reach areas more quickly and effectively. The Helios emitters are positioned closer to hard surfaces, thereby reducing UV-C disinfection time and improving overall efficacy.

Healthcare providers are turning to UV-C technology as a complement to traditional cleaning methods to combat healthcare-associated infections (HAIs). UV-C energy (at 254nm) is the peak germ-killing part of the ultraviolet spectrum.

According to the CDC, roughly one in every 20 hospitalized patients acquires an infection during the course of receiving treatment for another condition. HAIs create significant health risks and cost the healthcare industry billions of dollars each year. That toll has placed a high priority on innovative technologies such as UV-C disinfection.

The Surfacide Helios system is available in the U.S. and internationally. For more information as well as efficacy studies, visit Surfacide.com or call 844-390-3538.

About Surfacide
Surfacide provides an evidence-based, automatic UV-C room disinfection system that eradicates multi-drug resistant organisms, including C.Diff, MRSA, VRE, CRE and Acinetobacter. The Surfacide Helios® system implements three emitters into the patient environment to clean all areas of the patient room, including the bathroom and other hard-to-reach areas.  

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-finds-surfacide-uv-c-light-effective-as-an-adjunct-to-infection-control-in-a-pediatric-burn-hospital-300429816.html


'/>"/>
SOURCE Surfacide
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
(Date:8/3/2017)... SAN DIEGO , Aug. 3, 2017  Opioid ... crippling diseases driving up healthcare costs and threatening outcomes, ... the lab supply and IVD industry that support them, ... health care market researcher said that drugs of abuse, ... vendors and sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... database to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s ... faster technology with lower fees. Paragon will build a fully verifiable database to ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the United States ... two sides. There are not two sides to hatred, bigotry, discrimination, and a white ... and the NPEIV stands against all forms of such hatred and discrimination in this ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made ... thanks to an ambitious venture that conjoined the passions of an NBA star, a ... the Liberty community. These shoes will save lives from the rampant infections transmitted through ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston area ... Texas, is launching a regional charity effort to provide publicity assistance and generate ... Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that has ...
Breaking Medicine News(10 mins):